Stimulant psychosis: systematic review

Background Psychosis associated with stimulant use is an increasing problem, but there is little research evidence about the nature of the problem and its management. Aims To critically review the literature on stimulant psychosis and sensitisation. Method Systematic review of studies that have investigated stimulant use and psychosis in humans. The main outcome measures were increases in psychosis with stimulant use, and differences between stimulant users and non-users. Results Fifty-four studies met the inclusion criteria. Experimental studies show that a single dose of a stimulant drug can produce a brief increase in psychosis ratings (a ‘response’) in 50–70% of participants with schizophrenia and preexisting acute psychotic symptoms, unaffected by the presence of antipsychotic medication. Those with schizophrenia who do not have acute psychotic symptoms respond, but less frequently (30%). There has been little research into the longer-term effects of use. Conclusions Compliance with antipsychotic medication by someone with schizophrenia will not prevent a relapse or worsening of psychotic symptoms if stimulants are used. Low-dose antipsychotic treatment may be beneficial in stimulant users, to prevent sensitisation.

[1]  S. Southwick,et al.  Effects of Cocaine on Hospital Course in Schizophrenia , 1993, The Journal of nervous and mental disease.

[2]  K. Merchant,et al.  Clozapine and haloperidol block the induction of behavioral sensitization to amphetamine and associated genomic responses in rats. , 1998, Brain research. Molecular brain research.

[3]  J. Lieberman,et al.  Longitudinal assessment of methylphenidate effects on oral word production and symptoms in first-episode schizophrenia at acute and stabilized phases , 1999, Biological Psychiatry.

[4]  J. Lieberman,et al.  Methylphenidate increases thought disorder in recent onset schizophrenics, but not in normal controls , 1993, Biological Psychiatry.

[5]  R. de la Torre,et al.  Human pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"): psychomotor performance and subjective effects. , 2000, Journal of clinical psychopharmacology.

[6]  J. Lieberman,et al.  Mood responses of remitted schizophrenics to methylphenidate infusion , 2005, Psychopharmacology.

[7]  J. Lieberman,et al.  Methylphenidate challenge as a predictor of relapse in schizophrenia. , 1984, The American journal of psychiatry.

[8]  K. Brady,et al.  Cocaine-induced psychosis. , 1991, The Journal of clinical psychiatry.

[9]  M. Bell,et al.  Relationship of positive and negative symptoms to cocaine abuse in schizophrenia. , 1994 .

[10]  J. Lieberman,et al.  Behavioral response to methylphenidate and treatment outcome in first episode schizophrenia. , 1990, Psychopharmacology bulletin.

[11]  S. Strakowski,et al.  Lack of Enhanced Response to Repeated d-Amphetamine Challenge in First-Episode Psychosis: Implications for a Sensitization Model of Psychosis in Humans , 1997, Biological Psychiatry.

[12]  D. Janowsky,et al.  Provocation of schizophrenic symptoms by intravenous administration of methylphenidate. , 1973, Archives of general psychiatry.

[13]  J. Corwin,et al.  Partial improvement in negative schizophrenic symptoms after amphetamine , 2004, Psychopharmacology.

[14]  D. Efron,et al.  Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. , 1997, Pediatrics.

[15]  M. Galanter,et al.  Schizophrenic Patients and Cocaine Use: Antecedents to Hospitalization and Course of Treatment , 1998, Substance abuse.

[16]  R. Hamer,et al.  Amphetamine Challenge Test, response to treatment, and lateral ventricle size in schizophrenia , 1989, Biological Psychiatry.

[17]  C. Brabbins,et al.  Psychiatrists' knowledge of drug induced psychosis , 1996 .

[18]  H. Kleber,et al.  Abstinence symptomatology and psychiatric diagnosis in cocaine abusers. Clinical observations. , 1986, Archives of general psychiatry.

[19]  P. Goldman-Rakic,et al.  Long-Lasting Psychotomimetic Consequences of Repeated Low-Dose Amphetamine Exposure in Rhesus Monkeys , 1999, Neuropsychopharmacology.

[20]  L. Hollister,et al.  COMBINED DRUG THERAPY OF CHRONIC SCHIZOPHRENICS , 1961 .

[21]  T. Cooper,et al.  Amphetamine and negative symptoms of schizophrenia , 2005, Psychopharmacology.

[22]  J. Lieberman,et al.  Methylphenidate Response, Psychopathology and Tardive Dyskinesia as Predictors of Relapse in Schizophrenia , 1994, Neuropsychopharmacology.

[23]  Ellinwood Eh,et al.  Fundamental mechanisms underlying altered behavior following chronic administration of psychomotor stimulants. , 1980 .

[24]  E. Cherland,et al.  Psychotic Side Effects of Psychostimulants: A 5-Year Review , 1999, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[25]  R. Wyatt,et al.  Phenomenologic Comparison of the Idiopathic Psychosis of Schizophrenia and Drug‐Induced Cocaine and Phencyclidine Psychoses: A Retrospective Study , 1994, Clinical neuropharmacology.

[26]  W. Bunney,et al.  Long-term pimozide pretreatment differentially affects behavioral responses to dextroamphetamine in schizophrenia. Further exploration of the dopamine hypothesis of schizophrenia. , 1982, Archives of general psychiatry.

[27]  S. Satel,et al.  Cocaine-induced paranoia and psychosis proneness. , 1991, The American journal of psychiatry.

[28]  W. Bunney,et al.  Lack of behavioral supersensitivity to d-amphetamine after pimozide withdrawal. A trial with schizophrenic patients. , 1980, Archives of general psychiatry.

[29]  T. Kwapil A longitudinal study of drug and alcohol use by psychosis-prone and impulsive-nonconforming individuals. , 1996, Journal of abnormal psychology.

[30]  J. Lieberman,et al.  The Behavioral Effect of m-Chlorophenylpiperazine (mCPP) and Methylphenidate in First-Episode Schizophrenia and Normal Controls , 1995, Neuropsychopharmacology.

[31]  L. Judd,et al.  Methylphenidate hydrochloride effects on psychological tests in acute schizophrenic and nonpsychotic patients. , 1977, Archives of general psychiatry.

[32]  A. Iwanami,et al.  Patients with methamphetamine psychosis admitted to a psychiatric hospital in Japan , 1994, Acta psychiatrica Scandinavica.

[33]  S. Woods,et al.  Significant interaction between clozapine and cocaine in cocaine addicts. , 2000, Drug and alcohol dependence.

[34]  W. Bunney,et al.  Lithium attenuates the activation-euphoria but not the psychosis induced by d-amphetamine in schizophrenia , 2004, Psychopharmacology.

[35]  J. Lieberman,et al.  Dopaminergic mechanisms in idiopathic and drug-induced psychoses. , 1990, Schizophrenia bulletin.

[36]  R. Post,et al.  Cocaine, kindling, and psychosis. , 1976, The American journal of psychiatry.

[37]  Philip D. Harvey,et al.  Effects of Amphetamine on Visuospatial Working Memory Performance in Schizophrenia Spectrum Personality Disorder , 2000, Neuropsychopharmacology.

[38]  T. Roth,et al.  Sleepiness and motor vehicle accidents. , 1988, International clinical psychopharmacology.

[39]  J. Krystal,et al.  Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. , 1998, The American journal of psychiatry.

[40]  W. Bunney,et al.  Antipsychotic effects of pimozide in schizophrenia. Treatment response prediction with acute dextroamphetamine response. , 1982, Archives of general psychiatry.

[41]  J. Rotrosen,et al.  Amphetamine response and relapse risk after depot neuroleptic discontinuation , 2004, Psychopharmacology.

[42]  K. Carroll,et al.  One‐Year Follow‐Up Status of Treatment‐Seeking Cocaine Abusers: Psychopathology and Dependence Severity as Predictors of Outcome , 1993, The Journal of nervous and mental disease.

[43]  B. Winsberg,et al.  Methylphenidate augmentation therapy in schizophrenia. , 1992, Journal of clinical psychopharmacology.

[44]  S. Otsuki,et al.  Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis. , 1983, Biological psychiatry.

[45]  M. Alpert,et al.  Clinical effects of recent cocaine use on patients with acute schizophrenia. , 1995, The American journal of psychiatry.

[46]  John M. Davis,et al.  Behavioral and biochemical effects of methylphenidate in schizophrenic and nonschizophrenic patients , 1991, Biological Psychiatry.

[47]  W. Sargant,et al.  Observations on Benzedrine , 1937, British medical journal.

[48]  E. Bartlett,et al.  Selective Sensitization to the Psychosis-Inducing Effects of Cocaine: A Possible Marker for Addiction Relapse Vulnerability? , 1997, Neuropsychopharmacology.

[49]  D. V. van Kammen,et al.  Dextro-amphetamine diminishes negative symptoms in schizophrenia. , 1988, International clinical psychopharmacology.

[50]  T. Manschreck,et al.  Characteristics of freebase cocaine psychosis. , 1988, The Yale journal of biology and medicine.

[51]  T. Cooper,et al.  Acute d-amphetamine challenge in schizophrenia: Effects on cerebral glucose utilization and clinical symptomatology , 1994, Biological Psychiatry.

[52]  M. Mahowald,et al.  Psychiatric morbidity in narcoleptics on chronic high dose methylphenidate therapy. , 1995, The Journal of nervous and mental disease.

[53]  W. Bunney,et al.  d-Amphetamine-induced heterogeneous changes in psychotic behavior in schizophrenia. , 1982, The American journal of psychiatry.

[54]  W. Bunney,et al.  Prediction of early relapse after pimozide discontinuation by response to d-amphetamine during pimozide treatment. , 1982, Biological psychiatry.

[55]  G. Hogarty,et al.  Prediction of relapse in schizophrenic outpatients treated by drug and sociotherapy. , 1977, Archives of general psychiatry.

[56]  J. Lieberman,et al.  Brain morphology, dopamine, and eye-tracking abnormalities in first-episode schizophrenia. Prevalence and clinical correlates. , 1993, Archives of general psychiatry.

[57]  B. Brismar,et al.  Psychotic disorders among inpatients with abuse of cannabis, amphetamine and opiates. Do dopaminergic stimulants facilitate psychiatric illness? , 1999, European Psychiatry.

[58]  J. Rotrosen,et al.  Responses to apomorphine, amphetamine, and neuroleptics in schizophrenic subjects , 2004, Psychopharmacology.